Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Treasury Shares (2016 - 2020)

Historic Treasury Shares for Outlook Therapeutics (OTLK) over the last 6 years, with Q2 2020 value amounting to $2470.0.

  • Outlook Therapeutics' Treasury Shares fell 8468.79% to $2470.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $2470.0, marking a year-over-year decrease of 8468.79%. This contributed to the annual value of $2470.0 for FY2019, which is 8468.79% down from last year.
  • Latest data reveals that Outlook Therapeutics reported Treasury Shares of $2470.0 as of Q2 2020, which was down 8468.79% from $2470.0 recorded in Q1 2020.
  • In the past 5 years, Outlook Therapeutics' Treasury Shares ranged from a high of $1.2 million in Q4 2016 and a low of $2470.0 during Q3 2019
  • In the last 5 years, Outlook Therapeutics' Treasury Shares had a median value of $140023.0 in 2018 and averaged $425092.6.
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 5929.12% in 2016, then crashed by 9808.67% in 2019.
  • Over the past 5 years, Outlook Therapeutics' Treasury Shares (Quarter) stood at $1.2 million in 2016, then crashed by 74.73% to $309532.0 in 2017, then tumbled by 58.29% to $129095.0 in 2018, then crashed by 98.09% to $2470.0 in 2019, then changed by 0.0% to $2470.0 in 2020.
  • Its last three reported values are $2470.0 in Q2 2020, $2470.0 for Q1 2020, and $2470.0 during Q4 2019.